Oral riboflavin versus oral propranolol in migraine prophylaxis: An open label randomized controlled trial

Neurology Asia

Volumn 16, Issue 3, 2011, Pages 223-229

  Nambiar, Natasha J ^a   Aiyappa, Cuckoo ^a   Srinivasa, R ^a  

^a M S RAMAIAH MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

PROPRANOLOL; RIBOFLAVIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; NAUSEA; OPEN STUDY; PAIN ASSESSMENT; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ANALOG SCALE; VOMITING;

EID: 80053515148     PISSN: 18236138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Salomone S, Caraci F, Capasso A. Migraine: An overview. The Open Neurology Journal 2009; 3:64-71.
2. Silberstein SD, Saper JR, Freitag FG. Migraine: diagnosis and treatment. In: Silberstein SD, Lipton RB, Dalessio DJ, eds. Wolff's headache and other head pain. 7th ed. New York: Oxford University Press, 2001:121-238
3. World Health Organization. The World Health Report 2001: Mental Health: New Understanding, New Hope. http://www.who.int/whr/2001/en/index.html. Accessed January 12, 2009.
4. Berg J, Ramadan NM. Societal burden of the headache. In: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, eds: The Headaches. 3rd ed. Philadelphia: Lippincott Williams and Wilkin 2006;35-42.
5. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55:754-62.
6. Schoenen J, Lenaerts M, Bastings E. High-dose riboflavin as a prophylactic treat ment of migraine: results of an open pilot study. Cephalalgia 1994; 14(5):328-9.
7. Ferrari A, Sternieri E, Ferraris E, Bertolini A. Emerging problems in the pharmacotherapy of migraine: interactions between triptans and drugs for prophylaxis. Pharmacol Res 2003; 48:1-9.
8. Montagna P, Gallassi R, Medori R, et al. MELAS syndrome: characteristic migrainous and epileptic features and maternal transmission. Neurology 1998; 38:751-4.
9. Goto Y, Horai S, Matsuoka T, et al. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS): a correlative study of the clinical features and mitochondrial DNA mutation. Neurology 1992; 42:545-50.
10. Sandor PS, Afra J, Ambrosini A, Schoenen J. Prophylactic treatment of migraine with beta-blockers and riboflavin: differential effects on the intensity dependence of auditory evoked cortical potentials. Headache 2000; 40(1):30-5.
11. Schoenen J, Leneaerts M, Bastings E. High dose riboflavin as a prophylactic treatment of migraine: results of an open pilot study. Cephalalgia 1994; 14:328-9.
12. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998; 50:466-70.
13. Boehnke C, Reuter U, Flach U, et al. High-dose riboflavin treatment is efficacious in migraine prophylaxis:an open study in a tertiary care centre. Eur J Neurol 2004; 11:475-7.
14. Franca DS, Souza ALS, Almeida KR, Dolabella SS, Martinelli C, Coelho MM. B vitamins induce an antinociceptive effect in the acetic acid and formaldehyde models of nociception in mice. Eur J Pharmacol 2001; 421:157-64.
15. Granados-Soto V, Terán-Rosales F, Rocha-González HI, et al. Riboflavin reduces hyperalgesia and inflammation but not tactile allodynia in the rat. Eur J Pharmacol 2004; 492:35-40.